Teva CEO on decimated share price: "It's rational enough from a market point of view"

As the CEO of Israeli pharmaceutical company Teva, Kåre Schultz has some work ahead of him in order to convince the market there's light at the end of the tunnel.

Teva CEO Kåre Schultz | Photo: Lars Krabbe/ERH

There's no reason to be bitter about the plummeting share price of Israeli pharmaceutical company Teva, as it makes sense, according to CEO Kåre Schultz, who has not yet managed to generate value for the firm's hard-pressed shareholders.

"I'm alright with it. In my view, we've managed to save the company, reorganize it and bring down debts, but we're not done yet," says Schultz.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs